A Selective Modulator of Peroxisome Proliferator-Activated Receptor γ with an Unprecedented Binding Mode

• Published in: Journal of medicinal chemistry Vol. 63; no. 9; pp. 4555 - 4561
• Main Authors: Hanke, Thomas, Cheung, Sun-Yee, Kilu, Whitney, Heering, Jan, Ni, Xiaomin, Planz, Viktoria, Schierle, Simone, Faudone, Giuseppe, Friedrich, Marius, Wanior, Marek, Werz, Oliver, Windbergs, Maike, Proschak, Ewgenij, Schubert-Zsilavecz, Manfred, Chaikuad, Apirat, Knapp, Stefan, Merk, Daniel
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 14.05.2020; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; RISK; PIOGLITAZONE; ROSIGLITAZONE; MYOCARDIAL-INFARCTION
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.9b01786

The nuclear peroxisome proliferator-activated receptor γ has well-validated therapeutic potential in metabolic, inflammatory, and neurodegenerative pathologies, but its activation is also associated with marked adverse effects and novel modes of PPARγ modulation are required. Here, we report the discovery and profiling of a new PPARγ modulator chemotype endowed with remarkable potency and a distinct binding mode in the orthosteric PPARγ ligand-binding site. Its R-enantiomer evolved as a eutomer regarding PPARγ activation with a high eudysmic ratio. The new PPARγ modulator revealed outstanding selectivity over the PPARα and PPARδ subtypes and did not promote adipogenesis in primary human fibroblasts, discriminating it from established agonists.